Bimat: Advanced Therapy for Enhanced Eyelash Growth
Bimat
| Product dosage: 0.3mg | |||
|---|---|---|---|
| Package (num) | Per bottle | Price | Buy |
| 1 | 70.20 $ | 70.20 $ (0%) | 🛒 Add to cart |
| 2 | 58.50 $ | 140.40 $ 117.00 $ (17%) | 🛒 Add to cart |
| 3 | 50.70 $ | 210.60 $ 152.10 $ (28%) | 🛒 Add to cart |
| 4 | 49.72 $ | 280.80 $ 198.90 $ (29%) | 🛒 Add to cart |
| 5 | 46.80 $ | 351.00 $ 234.00 $ (33%) | 🛒 Add to cart |
| 6 | 44.85 $ | 421.20 $ 269.10 $ (36%) | 🛒 Add to cart |
| 7 | 43.46 $ | 491.40 $ 304.20 $ (38%) | 🛒 Add to cart |
| 8 | 42.41 $ | 561.60 $ 339.30 $ (40%) | 🛒 Add to cart |
| 9 | 40.30 $ | 631.80 $ 362.70 $ (43%) | 🛒 Add to cart |
| 10 | 38.61 $
Best per bottle | 702.00 $ 386.10 $ (45%) | 🛒 Add to cart |
Synonyms | |||
Bimat represents a significant advancement in ophthalmic therapeutics, specifically formulated to address hypotrichosis of the eyelashes. This prescription treatment is clinically proven to promote longer, thicker, and darker eyelashes through a well-understood mechanism of action. Its efficacy is supported by rigorous clinical trials, making it a trusted choice among dermatologists and ophthalmologists worldwide. Proper application and adherence to medical guidance are essential for achieving optimal results while minimizing potential risks.
Features
- Contains bimatoprost 0.03% as the active pharmaceutical ingredient
- Presented as a sterile, isotonic ophthalmic solution
- Supplied in multi-dose bottles with precision applicators
- Formulated to be preservative-free to minimize ocular irritation
- Developed through pharmaceutical-grade manufacturing processes
- Stability tested under controlled temperature and light conditions
Benefits
- Significantly increases eyelash length, thickness, and darkness
- Promotes transition of hair follicles from telogen to anagen phase
- Provides measurable results typically within 4-16 weeks of regular use
- Offers a non-invasive alternative to cosmetic procedures
- Maintains results with continued proper application
- Supported by extensive clinical research and post-market surveillance
Common use
Bimat is primarily indicated for the treatment of hypotrichosis of the eyelashes, characterized by inadequate or not enough eyelashes. It is prescribed for patients seeking to enhance the appearance of their natural eyelashes through pharmaceutical intervention. The product is commonly used by individuals who have experienced eyelash thinning due to aging, genetic factors, or certain medical conditions. Clinical studies demonstrate its effectiveness across diverse patient populations when used as directed under medical supervision.
Dosage and direction
Apply one drop of Bimat to the disposable sterile applicator once daily in the evening. Carefully draw the applicator across the skin of the upper eyelid margin at the base of the eyelashes, moving from the inner to the outer part of the lid. Do not apply to the lower eyelid. Use a fresh applicator for each eye to prevent cross-contamination. Avoid allowing the tip of the bottle to contact surrounding structures, fingers, or any other surface. Contact lenses should be removed prior to application and may be reinserted 15 minutes afterward.
Precautions
Bimat may gradually increase brown iris pigmentation, which is likely permanent. Eyelid skin darkening may occur, which may be reversible upon discontinuation. There is potential for hair growth to occur in areas where the solution frequently touches. Patients should be advised that these changes may alter their appearance. The solution should not be used by patients with active ocular inflammation or infection. Regular ophthalmologic examinations are recommended during treatment. Patients should discontinue use and consult their physician if any ocular reactions develop.
Contraindications
Bimat is contraindicated in patients with known hypersensitivity to bimatoprost or any component of the formulation. It should not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus. Nursing mothers should exercise caution, as it is unknown whether bimatoprost is excreted in human milk. The safety and effectiveness in pediatric patients have not been established. Patients with a history of herpes simplex keratitis should use with caution due to potential reactivation.
Possible side effects
The most common side effects include conjunctival hyperemia (red eyes), eyelid itching, ocular irritation, dry eye symptoms, and periocular skin hyperpigmentation. Less frequently reported effects include blepharitis, cataract, visual disturbance, and eye discharge. Rare but serious adverse reactions may include macular edema, uveitis, and trichiasis. Patients should report any persistent ocular discomfort, vision changes, or eyelid reactions to their healthcare provider promptly.
Drug interaction
No formal drug interaction studies have been conducted with Bimat. However, concomitant therapy with other ophthalmic medications should be administered with at least 5-minute intervals between applications. The use with prostaglandin analogs for glaucoma treatment may potentially enhance both therapeutic and adverse effects. Patients using multiple eye medications should inform their ophthalmologist to establish proper administration sequences and monitor for additive effects.
Missed dose
If a dose is missed, apply Bimat at the next scheduled time. Do not apply double the amount to make up for the missed dose. Maintain the regular once-daily application schedule. Consistency in application is important for optimal efficacy, but occasional missed doses are not expected to significantly impact overall treatment outcomes. Patients should establish a routine to support regular application.
Overdose
Ocular overdose may be flushed from the eye(s) with warm water. Systemic absorption following ocular administration is minimal. However, excessive application might increase the likelihood of adverse reactions. If accidental ingestion occurs, appropriate supportive measures should be instituted. Symptomatic treatment is recommended. There is no specific antidote for bimatoprost overdose. Medical attention should be sought if concerning symptoms develop.
Storage
Store Bimat at controlled room temperature 15°-30°C (59°-86°F). Protect from light and excessive heat. Keep the bottle tightly closed when not in use. Discard any unused solution 4 weeks after opening the bottle. Do not freeze the solution. Keep out of reach of children and pets. Do not use if the solution appears discolored or contains particles.
Disclaimer
This information is provided for educational purposes only and does not replace professional medical advice. Always consult a qualified healthcare provider for diagnosis and treatment recommendations. Individual results may vary. The manufacturer is not responsible for improper use or application. Patients should read the complete prescribing information before use and follow their physician’s instructions precisely.
Reviews
Clinical studies demonstrate patient satisfaction rates exceeding 85% after 16 weeks of proper use. Ophthalmologists report consistent efficacy in managing eyelash hypotrichosis with appropriate patient selection. Long-term safety data support continued use under medical supervision. Patients typically notice initial improvements within 8 weeks, with maximal results achieved by month 4. The product maintains a favorable benefit-risk profile when used as directed by qualified medical professionals.